Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2025 | How can AI tailor radiotherapy decision-making in breast cancer?

Philip Poortmans • 13 Mar 2025
BCC 2025
Breast Cancer

Philip Poortmans, MD, PhD, University of Antwerp, Antwerp, Belgium, Discusses the use of artificial intelligence (AI) in guiding radiotherapies in early breast-cancer. AI generates prognostic information to inform on patient selection for radiotherapy, defining dosage and volume parameters. This interview took place at the 2025 St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Philip Poortmans

The future of AI in guiding radiotherapy treatment for breast cancer
1:10
The future of AI in guiding radiotherapy treatment for breast cancer
Philip Poortmans • 13 Mar 2025
ULTIMO: cosmetic outcomes of UHF versus CF radiotherapy in breast cancer
1:38
ULTIMO: cosmetic outcomes of UHF versus CF radiotherapy in breast cancer
Philip Poortmans • 13 Mar 2025
Rationale behind tailoring radiation therapy in the pCR setting
2:46
Rationale behind tailoring radiation therapy in the pCR setting
Philip Poortmans • 16 May 2024
Controversies and uncertainties in axillary management
2:41
Controversies and uncertainties in axillary management
Philip Poortmans • 16 Mar 2023

Related Videos

Stress and depression linked to tumor transcriptional signatures in breast cancer
1:21
Stress and depression linked to tumor transcriptional signatures in breast cancer
Shipra Gandhi • 31 May 2026
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
1:13
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
Shipra Gandhi • 31 May 2026
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 1 Jun 2026
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
0:49
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
Shipra Gandhi • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals